264 related articles for article (PubMed ID: 27353537)
1. Biomarker Tests for Molecularly Targeted Therapies--The Key to Unlocking Precision Medicine.
Lyman GH; Moses HL
N Engl J Med; 2016 Jul; 375(1):4-6. PubMed ID: 27353537
[No Abstract] [Full Text] [Related]
2. Expansion of protections to all human research participants.
Maloney DM
Hum Res Rep; 2002 Dec; 17(12):1-2. PubMed ID: 12731499
[No Abstract] [Full Text] [Related]
3. Wiser investment for a healthier future.
Teutsch SM; Baciu AB; Mays GP; Getzen TE; Hansen MM; Geller AB
J Public Health Manag Pract; 2012; 18(4):295-8. PubMed ID: 22635180
[No Abstract] [Full Text] [Related]
4. Letter from North America: The United States government's comparative effectiveness research program.
Sakala C
Birth; 2009 Dec; 36(4):342-4. PubMed ID: 20002428
[No Abstract] [Full Text] [Related]
5. Institute of Medicine outlines priorities for comparative effectiveness research.
Kuehn BM
JAMA; 2009 Sep; 302(9):936-7. PubMed ID: 19724034
[No Abstract] [Full Text] [Related]
6. Organ transplant panel urges a broad sharing of livers.
Stolberg SG
N Y Times Web; 1999 Jul; ():A14. PubMed ID: 11648120
[No Abstract] [Full Text] [Related]
7. Science and government. Review for NCCAM is overdue.
Marcus DM; Grollman AP
Science; 2006 Jul; 313(5785):301-2. PubMed ID: 16857923
[No Abstract] [Full Text] [Related]
8. Implications of the Institute of Medicine Report: Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease.
Wagner JA; Ball JR
Clin Pharmacol Ther; 2015 Jul; 98(1):12-5. PubMed ID: 25833004
[TBL] [Abstract][Full Text] [Related]
9. Influencing cancer policy.
Herdman R; McGuire W; Simone J
Health Aff (Millwood); 2006; 25(3):800-7. PubMed ID: 16684746
[TBL] [Abstract][Full Text] [Related]
10. Expert panel sees poor leadership in U.S. AIDS battle.
Boffey PM
N Y Times Web; 1988 Jun; ():A1, B13. PubMed ID: 11646682
[No Abstract] [Full Text] [Related]
11. Healthcare on report. IOM president, just one year into his term, vows to build on organization's groundbreaking studies.
Morrissey J
Mod Healthc; 2003 Aug; 33(31):30-1. PubMed ID: 12931479
[No Abstract] [Full Text] [Related]
12. Research integrity. U.S. universities urged to do a better job.
Kaiser J
Science; 2002 Jul; 297(5580):321. PubMed ID: 12130761
[No Abstract] [Full Text] [Related]
13. Funding health sciences research: a strategy to restore balance.
Bloom FE; Bulger RE; Randolph MA
Clin Res; 1990 Dec; 38(4):671-85. PubMed ID: 2177388
[No Abstract] [Full Text] [Related]
14. Blueprint for a stronger Food and Drug Administration.
Curfman GD; Morrissey S; Drazen JM
N Engl J Med; 2006 Oct; 355(17):1821. PubMed ID: 17030844
[No Abstract] [Full Text] [Related]
15. New rules for research with human participants?
Berg J; Deming N
Hastings Cent Rep; 2011; 41(6):10-1. PubMed ID: 22238896
[No Abstract] [Full Text] [Related]
16. Medical devices and health--creating a new regulatory framework for moderate-risk devices.
Challoner DR; Vodra WW
N Engl J Med; 2011 Sep; 365(11):977-9. PubMed ID: 21830961
[No Abstract] [Full Text] [Related]
17. Federally funding human embryonic stem cell research: an administrative analysis.
Gross GS
Wis L Rev; 2000; 4():855-84. PubMed ID: 12664903
[No Abstract] [Full Text] [Related]
18. Codevelopment of genome-based therapeutics and companion diagnostics: insights from an Institute of Medicine roundtable.
McCormack RT; Armstrong J; Leonard D
JAMA; 2014 Apr; 311(14):1395-6. PubMed ID: 24522512
[No Abstract] [Full Text] [Related]
19. Stimulus funds force hard look at comparative effectiveness research.
Tuma RS
J Natl Cancer Inst; 2009 Aug; 101(15):1036-9. PubMed ID: 19638502
[No Abstract] [Full Text] [Related]
20. IOM: overhaul drug safety monitoring.
Kuehn BM
JAMA; 2006 Nov; 296(17):2075-6. PubMed ID: 17077364
[No Abstract] [Full Text] [Related]
[Next] [New Search]
